Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.

@article{Ojima2013GlucagonlikePR,
  title={Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.},
  author={Ayako Ojima and Yuji Ishibashi and Takanori Matsui and Sayaka Maeda and Yuri Nishino and Masayoshi Takeuchi and Kei Fukami and Sho-ichi Yamagishi},
  journal={The American journal of pathology},
  year={2013},
  volume={182 1},
  pages={132-41}
}
Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic nephropathy. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, contributes to diabetic nephropathy. We have found that glucagon-like peptide-1 (GLP-1) inhibits the AGE-induced inflammatory reactions in endothelial cells. However, effects of GLP-1 on the AGE-RAGE-ADMA axis are unknown. This study examined the effects of GLP-1 on reactive oxygen species (ROS) generation… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Advancedglycation endproducts , oxidative stress and diabetic nephropathy

S Yamagishi, MatsuiT
Oxid Med Cell Longev • 2010

Similar Papers

Loading similar papers…